HDL cholesterol response to GH replacement is associated with common cholesteryl ester transfer protein gene variation (-629C > A) and modified by glucocorticoid treatment

Robin P. F. Dullaart*, Gerrit van den Berg, Aafke M. van der Knaap, Janneke Dijck-Brouwer, Geesje M. Dallinga-Thie, Peter M. J. Zelissen, Wim J. Sluiter, Andre P. van Beek

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

6 Citaten (Scopus)


Objective: GH replacement lowers total cholesterol and low-density lipoprotein cholesterol (LDL-C) in GH-deficient adults, but effects on high-density lipoprotein (HDL) cholesterol (HDL-C) are variable. Both GH and glucocorticoids decrease cholesteryl ester transfer protein (CETP) activity, which is important in HDL metabolism. We determined the extent to which the changes in HDL-C in response to GH replacement are predicted by the -629C>A CETP promoter polymorphism, and questioned whether this association is modified by concomitant glucocorticoid treatment.

Design and methods: A total of 91 GH-deficient adults (63 receiving glucocorticoids) were genotyped for the -629 CETP C>A polymorphism. Fasting serum lipids were measured before and after 1.2 +/- 0.4 years of GH treatment (Genotropin, Pfizer Inc., Stockholm, Sweden).

Results: In the whole group, total cholesterol and LDL-C decreased (P

Conclusions: We suggest a common CETP variant-glucocorticoid treatment interaction concerning the effect of GH replacement on HDL-C. This may explain some of the reported variation in the HDL-C response to GH.

Originele taal-2English
Pagina's (van-tot)227-234
Aantal pagina's8
TijdschriftEuropean Journal of Endocrinology
Nummer van het tijdschrift2
StatusPublished - feb-2010

Citeer dit